C12N 9/6416
Metalloendopeptidases
Official title: {Metalloendopeptidases (3.4.24)}
C12N9/6416 (Metalloendopeptidases) appears on 41 US grants and 70 published applications in this corpus.
Search patents in C12N- Granted patents
- 41
- Published applications
- 70
- Assignees
- 54
- Inventors
- 160
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 1 |
| 2002 | 0 | 5 |
| 2003 | 0 | 3 |
| 2004 | 1 | 3 |
| 2005 | 1 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 2 | 4 |
| 2010 | 2 | 3 |
| 2011 | 2 | 0 |
| 2012 | 1 | 7 |
| 2013 | 3 | 0 |
| 2014 | 3 | 2 |
| 2015 | 2 | 0 |
| 2016 | 2 | 3 |
| 2017 | 1 | 4 |
| 2018 | 3 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 4 |
| 2022 | 1 | 2 |
| 2023 | 0 | 2 |
| 2024 | 3 | 4 |
| 2025 | 2 | 9 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bacillus thuringiensis toxin receptors and uses thereof17 Mar 2026US 12,577,284 B2Monsanto Technology LLC
- Enhancers of neurolysin activity17 Jun 2025US 12,331,333 B2Texas Tech University System
- Methods and compositions for inhibiting ADAM 9 biological activities11 Mar 2025US 12,247,232 B2Verra Therapeutics, Inc.
- Methods, apparatuses and systems for adolescent idiopathic scoliosis treatment26 Nov 2024US 12,150,977 B2
- Feed composition supplemented with a protease combination12 Mar 2024US 11,926,855 B2Kerry Group Services International Limited
- Bacillus thuringiensis toxin receptors and uses thereof30 Jul 2026US 2026/0217787 A1Monsanto Technology LLC
- Water-soluble unit dose article comprising a metalloprotease5 Mar 2026US 2026/0062650 A1The Procter & Gamble Company
- Gel composition for xenotransplantation or allotransplantation and manufacturing method of the same26 Feb 2026US 2026/0053989 A1Tzu Chi University
- Rna aptamer targeting of adam8 in cancer growth and metastasis25 Sep 2025US 2025/0297264 A1University of South Florida
- Methods and compositions for inhibiting adam9 biological activities12 Jun 2025US 2025/0188434 A1Verra Therapeutics, Inc.
Most cited
By later US patents
- Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV19US 6,926,894 B2Baxter Aktiengesellschaft · 2005
- Collagen-specific enzyme with platelet aggregation inhibition properties12US 5,139,944 ABiophram (UK) Limited · 1992
- Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV9US 7,501,117 B2Baxter Innovations GmbH · 2009
- Matrix metalloproteinase 11 vaccine7US 8,106,176 B2Instituto di Richerche di Biologia Molecolare P. Angeletti SpA · 2012
- Modified mutant collagenase and its use in fat melting and in scar reduction4US 8,617,543 B2Yolare Pharmaceuticals, LLC · 2013